Author:
Dipasquale Valeria,Cicala Giuseppe,Spina Edoardo,Romano Claudio
Abstract
Background: Many pediatric inflammatory bowel disease (IBD) patients are now using biosimilars of anti-tumor necrosis factor-α (TNF-α), with increasing trends in recent years. This study reviewed all available data regarding the use of biosimilars in children with IBD.Methods: PubMed, Google Scholar, Scopus, and CENTRAL databases were searched through keywords; inflammatory bowel diseases, Crohn’s disease, ulcerative colitis, biosimilar and child were combined using “AND” and “OR.” Original research articles involving pediatric patients receiving one of the biosimilar medications based on the anti-TNF-α biologic drugs approved for pediatric IBD treatment, independently from efficacy and drug response, were included.Results: Nine studies were included in the evidence synthesis. CT-P13 was the biosimilar used in all studies. Four studies assessed the induction effectiveness of CT-P13. Clinical response and remission rates of biosimilar treatment were 86–90% and 67–68%, respectively, and they were not significantly different to the originator group. Five prospective studies on patients elected to switch from originator IFX to CT-P13 yielded similar results. Adverse events related to CT-P13 were mostly mild. The most frequently reported were upper respiratory tract infections. The switch from the originator had no significant impact on immunogenicity.Conclusion: The current review showed reported CT-P13 effectiveness as measured by clinical response and/or remission rates after induction or during maintenance and suggest that there is no significant difference with that of the originator IFX. Further studies are warranted, including clinical, and pharmacovigilance studies.
Subject
Pharmacology (medical),Pharmacology
Reference37 articles.
1. Report of the ECCO Pathogenesis Workshop on Anti-TNF Therapy Failures in Inflammatory Bowel Diseases: Definitions, Frequency and Pharmacological Aspects;Allez;J. Crohns. Colitis.,2010
2. Clinical Trial Development for Biosimilars;Alten;Semin. Arthritis Rheum.,2015
3. A Budget Impact Model for Biosimilar Infliximab in Crohn's Disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia;Brodszky;Expert Rev. Pharmacoecon. Outcomes Res.,2016
4. Use of Infliximab Biosimilar versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort;Chanchlani;J. Pediatr. Gastroenterol. Nutr.,2018
5. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness;Cheon;Adv. Ther.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献